William  Ho net worth and biography

William Ho Biography and Net Worth

Insider of RAPT Therapeutics
Bill joined RAPT Therapeutics as Chief Medical Officer in 2015, bringing with him extensive experience both in clinical immunotherapy and in the translational and clinical development of novel therapeutics to treat cancer. He joined RAPT Therapeutics after serving as the Vice President of Clinical Development at Igenica Biotherapeutics, where he led the clinical development of antibody-based therapeutics. Prior to Igenica, Bill served as a Senior Medical Director in the Exploratory Clinical Development (BioOncology) group at Genentech, where for seven years he led the development of multiple small molecule, antibody, and antibody-drug conjugate programs from IND filing to Phase III, including clinical development of Gazyva® (obinutuzumab), Venclexta™ (venetoclax) and Polivy™ (polatuzumab vedotin-piiq).

Bill received his A.B. in Molecular Biology from Princeton University and both his M.D. and his Ph.D. in Microbiology and Immunology from the Stanford University School of Medicine, where he studied cellular immunology in the laboratory of Mark Davis, Ph.D. Bill completed his internship and residency in Internal Medicine at the University of California, San Francisco, and received his training in Medical Oncology at the University of Washington and Fred Hutchinson Cancer Research Center, where he studied adoptive immunotherapy methods to treat leukemia.

What is William Ho's net worth?

The estimated net worth of William Ho is at least $18,324.40 as of December 21st, 2023. Dr. Ho owns 15,020 shares of RAPT Therapeutics stock worth more than $18,324 as of March 30th. This net worth estimate does not reflect any other investments that Dr. Ho may own. Additionally, Dr. Ho receives a salary of $620,320.00 as Insider at RAPT Therapeutics. Learn More about William Ho's net worth.

How old is William Ho?

Dr. Ho is currently 58 years old. There are 6 older executives and no younger executives at RAPT Therapeutics. The oldest executive at RAPT Therapeutics is Dr. David Wustrow, Senior Vice President of Drug Discovery & Preclinical Development, who is 65 years old. Learn More on William Ho's age.

What is William Ho's salary?

As the Insider of RAPT Therapeutics, Inc., Dr. Ho earns $620,320.00 per year. The highest earning executive at RAPT Therapeutics is Dr. Brian Russell Wong M.D., Ph.D., CEO, President & Director, who commands a salary of $861,240.00 per year. Learn More on William Ho's salary.

How do I contact William Ho?

The corporate mailing address for Dr. Ho and other RAPT Therapeutics executives is 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA, 94080. RAPT Therapeutics can also be reached via phone at (650) 489-9000 and via email at investors@rapt.com. Learn More on William Ho's contact information.

Has William Ho been buying or selling shares of RAPT Therapeutics?

William Ho has not been actively trading shares of RAPT Therapeutics during the last quarter. Most recently, William Ho sold 2,500 shares of the business's stock in a transaction on Thursday, December 21st. The shares were sold at an average price of $21.68, for a transaction totalling $54,200.00. Following the completion of the sale, the insider now directly owns 15,020 shares of the company's stock, valued at $325,633.60. Learn More on William Ho's trading history.

Who are RAPT Therapeutics' active insiders?

RAPT Therapeutics' insider roster includes Dirk Brockstedt (Insider), William Ho (Insider), and Wendye Robbins (Director). Learn More on RAPT Therapeutics' active insiders.

William Ho Insider Trading History at RAPT Therapeutics

William Ho Buying and Selling Activity at RAPT Therapeutics

This chart shows William Ho's buying and selling at RAPT Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$400k-$200k$0$200k$400kTotal Insider BuyingTotal Insider Selling

RAPT Therapeutics Company Overview

RAPT Therapeutics logo
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company
Read More

Today's Range

Now: $1.22
Low: $1.19
High: $1.41

50 Day Range

MA: $1.19
Low: $1.05
High: $1.56

2 Week Range

Now: $1.22
Low: $0.79
High: $9.65

Volume

581,484 shs

Average Volume

1,278,691 shs

Market Capitalization

$161.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A